Truncations of Titin Causing Dilated CardiomyopathyDaniel S. Herman, Christine E. Seidman, Lien Lam et al.|New England Journal of Medicine|2012Cited by 1.5k
Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice GuidelineRay E. Hershberger, Jeffrey A. Towbin, JoAnn Lindenfeld et al.|Journal of Cardiac Failure|2009Cited by 705
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y. Ho, Eugene Braunwald, Sharlene M. Day et al.|Nature Medicine|2021Cited by 132
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G. Ireland, Carolyn Y. Ho, Danielle S. Burstein et al.|Circulation Heart Failure|2024Cited by 6
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin‐Cristian Topriceanu, Carolyn Y. Ho, Joseph W. Rossano et al.|Circulation Heart Failure|2025Cited by 3